| Identification | Back Directory | [Name]
CDDO-2-P-Im | [CAS]
1883650-95-0 | [Synonyms]
CPD1589
CPDB1589
CDDO-2-P-Im
CDDO-3P-Imidazolide
Oleana-1,9(11)-diene-2-carbonitrile, 3,12,28-trioxo-28-[4-(3-pyridinyl)-1H-imidazol-1-yl]- | [Molecular Formula]
C39H46N4O3 | [MOL File]
1883650-95-0.mol | [Molecular Weight]
618.81 |
| Chemical Properties | Back Directory | [Boiling point ]
771.1±70.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (404.00 mM) | [form ]
Solid | [pka]
3.34±0.12(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model[1]. CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R)[2]. | [in vivo]
CDDO-3P-Im is more stable than CDDO-Im in pharmacokinetic studies[1].
CDDO-3P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo[1].
CDDO-3P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice[1].
| Animal Model: | Seven week-old female A/J mice[1] | | Dosage: | 50 mg/kg, 200 mg/kg | | Administration: | Diet; for 16 weeks | | Result: | Decreased the number, the size and the severity of tumors. |
| [References]
[1] Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. DOI:10.1016/j.phrs.2015.07.024
[2] Yuanyuan Wang, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2020 Nov 21;113030. DOI:10.1016/j.ejmech.2020.113030 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|